Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inosine SCHEMBL15903470 | 1.00 | PAX8 (0.57) | PAX8HPGDLMNATP53ALDH1A1 | |
| Inosine SCHEMBL7633338 | 1.00 | PAX8 (0.57) | PAX8HPGDLMNATP53ALDH1A1 | |
| Inosine SCHEMBL20138538 | 1.00 | PAX8 (0.57) | PAX8HPGDLMNATP53ALDH1A1 | |
| Inosine SCHEMBL1682742 | 1.00 | PAX8 (0.57) | PAX8HPGDLMNATP53ALDH1A1 | |
| SCHEMBL21063147 | 0.90 | LMNA (0.47) | PAX8HPGDLMNATP53ALDH1A1 | |
| Inosine SCHEMBL15348254 | 0.89 | SLC29A1 (0.57) | PAX8LMNAALDH1A1PMP22ADORA3 | |
| Inosine SCHEMBL14126094 | 0.89 | SLC29A1 (0.57) | PAX8LMNAALDH1A1PMP22ADORA3 | |
| Adenosine SCHEMBL29840889 | 0.86 | ADORA2A (0.52) | PAX8HPGDLMNATP53ALDH1A1 | |
| Thioinosine SCHEMBL29988995 | 0.85 | ALDH1A1 (0.66) | PAX8HPGDLMNATP53ALDH1A1 | |
| Thioinosine SCHEMBL18314189 | 0.85 | ALDH1A1 (0.66) | PAX8HPGDLMNATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549960-B1 | Topical transdermal method for delivering nutrients through the skin for expedited wound healing and skin rejuvination | NEVILLE PHARMACEUTICAL, INC. (US) | 2017-01-24 | — | — | US | claimed |
| US-9439940-B2 | Topical transdermal method for delivering nutrients through the skin for expeditied wound healing and skin rejuvenation | NEVILLE PHARMACEUTICAL, INC. (US) | 2016-09-13 | — | — | US | claimed |
| US-20160082068-A9 | Topical Transdermal Method for Delivering Nutrients Through the Skin for Expeditied Wound Healing and Skin Rejuvenation | NEVILLE PHARMACEUTICAL, INC. | 2016-03-24 | — | — | US | claimed |
| US-20130022687-A1 | TOPICAL TRANSDERMAL METHOD FOR DELIVERING NUTRIENTS THROUGH THE SKIN FOR EXPEDITED WOUND HEALING | FITZGERALD JR JOHN JAMES (US) | 2013-01-24 | — | — | US | claimed |
| WO-1997021443-A1 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | BALAZOVSKIY MARK BORISOVICH (RU) | 1997-06-19 | — | — | WO | claimed |
| US-4405610-A | INOSINE, LYSINE OROTATE | KRNJEVIC HRVOJE (YU) | 1983-09-20 | — | — | US | claimed |
| US-20250275926-A1 | MULTILAYER FORMULATION COMPRISING MODIFIED TAPIOCA STARCH FOR CONTROLLED-RELEASE OF ACTIVE AGENTS | ACCESS BUSINESS GROUP INT LLC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20240415095-A1 | PET HEALTH AQUEOUS COMPOSITION AND ASSOCIATED CONTAINER | SUSU PETS LLC (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2023205222-A1 | MULTILAYER FORMULATION COMPRISING MODIFIED TAPIOCA STARCH FOR CONTROLLED-RELEASE OF ACTIVE AGENTS | ACCESS BUSINESS GROUP INTERNATIONAL LLC (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20220369592-A1 | Container for an Aqueous Composition | SUSU PETS, LLC (US) | 2022-11-24 | — | — | US | disclosed |
| US-11491175-B2 | Synergistic bioactive compositions for enhancing cellular energy | Celagenex Research (India) Pvt. Ltd. (IN) | 2022-11-08 | — | — | US | disclosed |
| US-20220125815-A1 | SYNERGISTIC BIOACTIVE COMPOSITIONS FOR ENHANCING CELLULAR ENERGY | Celagenex Research (India) Pvt. Ltd. (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11298330-B2 | Magnesium compositions and methods of use | NEUROCENTRIA, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-1069215-C | Anti-hypoxic drug | KARSANOV NV (GE) | 2001-08-08 | — | — | CN | disclosed |
| US-6251857-B1 | USING OXIDIZED GLUTATHIONE (ALSO KNOWN AS GLUTATHIONE DISULFIDE AND GSSG), DERIVATIVE OR SALT THEREOF; TREATING NEOPLASTIC, INFECTIOUS, HEMATOLOGIC AND IMMUNOLOGIC DISEASES | NOVELOS THERAPEUTICS, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6165979-A | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof | NOVELOS THERAPEUTICS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0869809-A1 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | Balazovsky, Mark Borisovich (RU) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997021444-A9 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997021444-A1 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | BALAZOVSKY MARK BORISOVICH (RU) | 1997-06-19 | — | — | WO | disclosed |
| US-4405610-A | INOSINE, LYSINE OROTATE | KRNJEVIC HRVOJE (YU) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125815-A1 | SYNERGISTIC BIOACTIVE COMPOSITIONS FOR ENHANCING CELLULAR ENERGY | ATIC, ADORA2A, NT5C2 | PAX8 2370/4885HPGD 141/4885LMNA 789/4885 |
| US-20250275926-A1 | MULTILAYER FORMULATION COMPRISING MODIFIED TAPIOCA STARCH FOR CONTROLLED-RELEASE OF ACTIVE AGENTS | SI, AMY1A, GANC | PAX8 4307/4885HPGD 2944/4885LMNA 1967/4885 |
| US-11491175-B2 | Synergistic bioactive compositions for enhancing cellular energy | ATIC, ADORA2A, NT5C2 | PAX8 2370/4885HPGD 141/4885LMNA 789/4885 |
| US-11298330-B2 | Magnesium compositions and methods of use | SLC5A6, SLC6A6, SLC6A5 | PAX8 4447/4885HPGD 775/4885LMNA 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.